Fig. 1.
mTORC1 signaling inhibition by RAD001 augments life span by decreasing thyroid tumor growth. (A) Kaplan–Meier survival curves for TRβPV/PVPten+/− mice treated or not with RAD001. TRβPV/PVPten+/− mice received the placebo or RAD001 (10 mg/kg body wt) twice a week by oral gavage from 6 weeks of age until they had to be euthanized because of sickness. (B) Thyroid glands of TRβPV/PVPten+/− mice, treated or not with RAD001, were dissected and weighed. The data are presented as ratios of thyroid weight to body weight. The difference in the thyroid weight between TRβPV/PVPten+/− mice treated or not with RAD001 is significant (P < 0.001), as determined by Student's t-test analysis. (C) Body weights of TRβPV/PVPten+/− mice receiving placebo or RAD001. Student's t-test analysis did not show any significant difference (P = 0.096; NS, not significant).